Can you take Ramelteon with Tyrvaya?

The varenicline in Tyrvaya has a moderate potential interaction with Acute Alcohol Intoxication.

Varenicline can enhance the response to alcohol and patients may experience increased intoxicating effects. In patients who may use alcohol excessively, it should be kept in mind that the potentiation may increase the danger associated with the use of alcohol. Advise patients to reduce the amount of alcohol they consume and to use caution driving or operating machinery or engaging in other potentially hazardous activities while taking varenicline until they know how this agent may affect them.

The varenicline in Tyrvaya has a moderate potential interaction with Cardiovascular Conditions and Disorders.

There have been reports of cardiovascular events, including ischemic and hemorrhagic events in patients taking varenicline. Caution is recommended when prescribing this agent. Patients should be monitored for signs of new or worsening symptoms of cardiovascular disease and appropriate therapy should be instituted according to medical guidelines.

Ramelteon has a major potential interaction with Depression.

A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics. Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations. These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation. Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders. Patients should be monitored for any changes in mood or behavior. It may be prudent to refrain from dispensing large quantities of medication to these patients.

The varenicline in Tyrvaya has a major potential interaction with Depressive Psychosis.

Serious neuropsychiatric events including, but not limited to, depression, suicidal ideation, suicide attempt, and completed suicide have been reported in patients taking varenicline. Caution is recommended and patients should be observed for neuropsychiatric symptoms including changes in behavior, hostility, agitation, depressed mood, and suicide-related events, including ideation, behavior, and attempted suicide.

Ramelteon has a moderate potential interaction with Glaucoma/Intraocular Hypertension.

Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.

The varenicline in Tyrvaya has a moderate potential interaction with Heart Attack.

There have been reports of cardiovascular events, including ischemic and hemorrhagic events in patients taking varenicline. Caution is recommended when prescribing this agent. Patients should be monitored for signs of new or worsening symptoms of cardiovascular disease and appropriate therapy should be instituted according to medical guidelines.

The varenicline in Tyrvaya has a moderate potential interaction with History - Cerebrovascular Disease.

There have been reports of cardiovascular events, including ischemic and hemorrhagic events in patients taking varenicline. Caution is recommended when prescribing this agent. Patients should be monitored for signs of new or worsening symptoms of cardiovascular disease and appropriate therapy should be instituted according to medical guidelines.

The varenicline in Tyrvaya has a moderate potential interaction with History - Myocardial Infarction.

There have been reports of cardiovascular events, including ischemic and hemorrhagic events in patients taking varenicline. Caution is recommended when prescribing this agent. Patients should be monitored for signs of new or worsening symptoms of cardiovascular disease and appropriate therapy should be instituted according to medical guidelines.

Ramelteon has a moderate potential interaction with Liver Disease.

In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver. Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function. Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly. Laboratory testing is recommended prior and during treatment.

The varenicline in Tyrvaya has a major potential interaction with Psychiatric Disorders.

Serious neuropsychiatric events including, but not limited to, depression, suicidal ideation, suicide attempt, and completed suicide have been reported in patients taking varenicline. Caution is recommended and patients should be observed for neuropsychiatric symptoms including changes in behavior, hostility, agitation, depressed mood, and suicide-related events, including ideation, behavior, and attempted suicide.

Ramelteon has a major potential interaction with Renal Dysfunction.

Some anxiolytic, sedative and hypnotic drugs have not been studied in patients with severe renal impairment and should not be used on these patients.

The varenicline in Tyrvaya has a moderate potential interaction with Renal Dysfunction.

Varenicline is substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Dose reduction is not required in patients with mild to moderate renal impairment. Dosage adjustment is needed in patients with severe renal impairment, and those with end-stage renal disease undergoing hemodialysis. Varenicline has been shown to be dialyzed in patients with end-stage renal disease. Monitoring of renal function is recommended.

The varenicline in Tyrvaya has a moderate potential interaction with Seizures.

Seizures have been reported with varenicline therapy. Therapy with this drug should be administered with caution and monitoring is recommended in patients with a history of seizures or other factors that can lower the seizure threshold.

Ramelteon has a major potential interaction with Sleep Apnea.

The use of ramelteon could exacerbate symptoms of sleep apnea, and has not been studied in patients with severe sleep apnea. Ramelteon is not recommended in patients with severe sleep apnea.

Ramelteon has a moderate potential interaction with Urinary Retention.

Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.